Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Humanized anti-human CD19 antibodies and methods of use
US12215152B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12215152-B2 |
| Application number | US-202217578655-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2022 |
| Priority date | Oct 1, 2015 |
| Publication date | Feb 4, 2025 |
| Grant date | Feb 4, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody that specifically binds to human CD19, wherein the antibody comprises: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08. 2. The antibody according to claim 1 , wherein the antibody is a monoclonal antibody. 3. The antibody according to claim 1 , wherein the antibody is a human, humanized or chimeric antibody. 4. The antibody according to claim 1 , wherein the antibody is an antibody fragment that specifically binds to human CD19. 5. The antibody according to claim 1 , wherein the antibody comprises: a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 09 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 27. 6. A pharmaceutical formulation, comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier. 7. A method of treating an individual having a B-cell cancer, comprising the step of administering to the individual an effective amount of the antibody according to claim 1 . 8. A method of depleting B-cells in an individual in need thereof, comprising the step of administering to the individual an effective amount of the antibody according to claim 1 to deplete B-cells.
Assignees
Inventors
Classifications
Complement-dependent cytotoxicity [CDC] · CPC title
Antibody-dependent cellular cytotoxicity [ADCC] · CPC title
Complementarity determining region [CDR] · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12215152B2 cover?
- Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino a…
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).